THE USE OF TIAGABINE FOR TREATMENT OF DIABETIC NEUROPATHY AND MIGRAINE

Abstract: (R)-N-[4,4-Bis(3-methyl-2-thienyl)-3-butenyl]nipecotic acid and salts thereof are effective GABA uptake inhibitory compounds and exert pharmacological effects on pain associated with diabetic neuropathy and migraine.

Description: THE USE OF TIAGABINE FOR TREATMENT OF DIABETIC NEUROPATHY AND MIGRAINE BACKGROUND OF THE INVENTION In the last two decades, intensive pharmacological research concerning gamma- aminobutyric acid (GABA), a neurotransmitter in the central nervous system, has taken place. Compounds which increase GABA activity are useful in the treatment of anxiety, epilepsy and muscular and movement disorders. Furthermore, these compounds can be used as sedatives. In U.S. Pat. Nos. 4,383,999 and 4,514,414 (Smithkline Beckman Corporation) some derivatives of N-(4-phenylbuten-3-yl)azaheterocyclic carboxylic acids which have, furthermore, inter alia, phenyl, 4-fluorophenyl, cyclohexyl or thienyl in the 4-position, are described. It is stated therein that the compounds are useful as inhibitors of GABA uptake. According to J. Pharm. Exp. Therap., 228 (1984), 109 et seq., N-(4,4-diphenyl-3- butenyl)nipecotic acid (designated SK&F 89976A). N-(4,4-diphenyl-3-butenyl)guvacine (designated SK&F 100330A), N-(4,4-diphenyl-3-butenyl)-5-homoproline (designated SK&F 100561) and N-(4-phenyl-4-(2-thienyl)-3-butenyl)nipecotic acid (designated SK&F 100604J) are active inhibitors of GABA uptake. It is further well recognized in the art that fi-homo-proline, nipecotic acid and guvacine are biological equivalents, at least as far as their GABA-like effects regards. See for example Progress in Medicinal Chemistry 21, 67-120 (1985); ed. Ellis West; Elsevier Science Publishers; Molecular and Cellular Biochemistry 31, 105-121 (1980), and /. Pharm. Exp. Therap., 228 (1984), 109 et seq. US 5,010,090 teaches the use of N-(Butenyl Substituted) Aza-Hetreocyclic Carboxylic Acids as exhibiting GABA uptake inhibitory properties. In particular, N-[4,4- Bis(3-methyl-2-thienyl)-3-butenyl]nipecotic acid and salts thereof are effective GABA uptake inhibitory compounds. These compounds have been found to be effective in the treatment of chronic pain. A study evaluated tiagabine HC1 in animal models of neuropathic and nociceptive pain. An Evaluation of the GABA Uptake Blocker Tiagabine in Animal Models of Neuropathic and Nociceptive Pain, A. Giardina et al. The study did not evaluate the effects of tiagabine HC1 in treating humans or pain associated with diabetic polyneuropathy and migraine. FIGURES Figure 1 depicts a list of the BPI items and the Change in Brief Pain Inventory in the Double-blind study comparing tiagabine XR to placebo. The ratings for the BPI items may range from 0-10 (except 0%-100% for item 3). The results indicated that tiagabine XR improved scores in all 12 parameters and the positive effect of tiagabine XR was statistically significant in items 3 and 11. Mean changes in the two scores are displayed as improvements from baseline such as that a positive change reflects improvement and a negative change reflects worsening. Figure 2 is a listing of the BPI items asked during the double-blind study. DETAILED DESCRIPTION OF THIS INVENTION It has been found that (R)-N-[4,4-Bis(3-methyl-2-thienyl)-3-butenyl]nipecotic acid and salts thereof are effective GABA uptake inhibitory compounds and exert pharmacological effects on pain associated with diabetic neuropathy and migraine. (R)- N-[4,4-Bis(3-methyl-2-thienyl)-3-butenyl]nipecotic hydrochloride (Tiagabine HC1, (Gabitril®) is sold commercially as an anti-epileptic. It is to be understood that isomers, including enantiomers, are included within the scope of this invention. US 5,010,090 teaches the synthesis and use of N-(Butenyl Substituted) Aza-Hetreocyclic Carboxylic Acids as exhibiting GABA uptake inhibitory properties. US 5,010,090 is hereby entirely incorporated by reference. An extended release formulation of (R)-N-[4,4-Bis(3-methyl-2-thienyl)-3- butenyljnipecotic acid hydrochloride (Tiagabine XR) (Formula G, 7507-9; Abbott Laboratories, IL.) was used for the treatment of pain associated with diabetic polyneuropathy. Tiagabine XR formulations useful include tiagabine and high molecular weight polyethylene oxide formulations that are exemplified in WO 99/37302, which published July 29, 1999. WO 99/37302 is hereby fully incorporated by reference. A single-center pilot study with an initial Open-Label Phase, followed by a randomized, double-blind, placebo-controlled, two-period, crossover phase, for subjects who demonstrated a reduction in their pain during the Open-Label Phase. The Open- Label Phase consisted of a Screening Period of up to 14 days and an up to 6-week Dose- Evaluation Period. The Double-Blind Phase consisted of two 1 to 5 week(s) treatment periods, each preceded by a 1-week Washout Period. The actual duration of the study was to have varied from subject to subject and was to range from 9 to 19 weeks for those who qualified for the Double-Blind Phase, depending on the maximum tolerated dose (MTD) of tiagabine XR established during the Open-Label Phase. The Open-Label Phase study evaluated 35 patients with painful diabetic polyneuropathy. Patients were initially titrated to their maximum tolerated dose of an extended release formulation of tiagabine hydrochloride (tiagabine XR) (Abbott Laboratories, Abbott Park, IL.) and were assessed by the Brief Pain Inventory (BPI). the BPI is hereby incorporated by reference. Patients successfully tolerating a daily dose of at least 12 mg (max: 60 mg) who demonstrated pain relief of at least three units on the worst/average pain items of the BPI were randomized, washed out, and re-titrated to their previously tolerated dose in a two-period, double-blind, placebo-controlled crossover phase. Males or non-pregnant, non-lactating females at least 18 years of age, diagnosed with stable chronic pain for at least 3 months, who met diagnostic criteria for generalized, symmetrical, painful diabetic polyneuropathy and had a pain rating of 3 units or higher on the worst pain item of the BPI at Visit 1 were eligible for study participation. Figure 2 provides a listing of the BPI items. Additionally, subjects who were on a fixed-schedule analgesic regimen must have been on a stable dose for 14 days prior to Visit 1. Subjects with a current seizure disorder or with a significant neurologic or psychiatric illness or impairment were not eligible for study participation. Subjects entering the Dose-Evaluation started tiagabine XR dosing at 12 mg/day for 1 week. Each week thereafter the dose of tiagabine XR was increased by 12 mg/day up to a maximum of 60 mg/day. The Dose-Evaluation Period ended after 1 week of stable dosing at the MTD. Subjects who demonstrated a reduction from Visit 1 of at least 2 units in either the worst pain or average pain items of the BPI and met all other randomization criteria entered the Double-Blind Phase. Subjects who met the criteria for entry into the Double-Blind Phase were randomly assigned in equal numbers to one of two treatment sequences: Sequence Group 1 : Placebo (Treatment Period I): tiagabine XR (Treatment Period II) Sequence Group 2: Tiagabine XR (Treatment Period 1): placebo (Treatment Period II) . The Double-Blind Phase consisted of two equal-length treatment periods; each preceded by a 1-week Washout Period. Throughout the study, the BPI was used to assess the subject's pain Seventeen subjects completed the open-label dose evaluation period. Five did not identify sufficient pain reduction (3 units in either the worst pain or average pain items of the BPI) to qualify for randomization. One declined for personal reasons. All 11 randomized subjects completed the Double-Blind Phase of the study. Statistically significant differences favoring tiagabine XR were observed for: 1) change in percent pain relief in the last 24 hours and 2) extent that pain interfered with sleep during the last 24 hours (see Figure 1). Improvement trends favoring tiagabine XR were observed in all planned BPI variables. All randomized subjects completed the study. In this study, tiagabine XR was safe and demonstrated a consistent trend in pain improvement in patients with diabetic polyneuropathy. The statistically significant differences (P<0.05) during the double-blind phase favoring tiagabine XR were observed for the changes in percent of pain relief that the treatment had provided in the last 24 hours and the extent that pain had interfered with sleep in the last 24 hours. Improvement favoring tiagabine XR, though not statistically significantly different from placebo, were observed in all the other pre-planned BPI variables. The most notable treatment differences occurred in the BPI items pertaining to the extent that pain in the last 24 hours had interfered with relations to people, general activity, enjoyment of life, and mood. Tiagabine XR demonstrated positive effects in both the Dose-Evaluation Period (open-label treatment) and the Double-Blind Phase.

Claims: WE CLAIM: 1. A method of treating pain associated with diabetic polyneuropathy by administering a pharaceutically effective amount of the compound (R)-N-[4,4- Bis(3-methyl-2-thienyl)-3-butenyl]nipecotic acid hydrochloride. 2. A method of claim 1 wherein said (R)-N-[4,4-Bis(3-methyl-2-thienyl)-3- butenyljnipecotic acid hydrochloride is in an extended release formulation. 3. A method of treating migraine by administering a pharaceutically effective amount of (R)-N-[4,4-Bis(3-methyl-2-thienyl)-3-butenyl]nipecotic acid hydrochloride. 4. A method of claim 3 wherein said (R)-N-[4,4-Bis(3-methyl-2-thienyl)-3- butenyl]nipecotic acid hydrochloride is in an extended release formulation.

Inventors: COLLINS STEPHEN D, DEATON ROGER L, GIARDINA WILLIAM J, GILBERT ADRIENNE L, COLLINS, STEPHEN, D., DEATON, ROGER, L., GIARDINA, WILLIAM, J., GILBERT, ADRIENNE, L.
Applicants: ABBOTT LAB, ABBOTT LABORATORIES
Application year: 2001
Main classification: A61K31
IPC codes: A61K9, A61K31, A61P25